Adaptive Biotechnologies Corporation (ADPT) Research

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

Market snapshot

Symbol
ADPT
Price
$17.53
Day change
+4.47%
Market cap
$2.8B
P/E ratio
-54.88x
52-week range
9.955-20.76
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$21.33

Recent news

  • Adaptive Biotechnologies Business Separation May Unlock Greater Value

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.

  • Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading higher during Tuesday's session as the company has announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.

  • Adaptive Biotechnologies plans separation of immune medicine platform

    Adaptive Biotechnologies said on Monday it planned to separate its immune medicine ​business from its residual cancer-testing unit, ‌as it reviews options for the drug-discovery business and focuses on testing.

Peer companies

  • Beam Therapeutics Inc. (BEAM)
  • Cidara Therapeutics, Inc. (CDTX)
  • Catalyst Pharmaceuticals, Inc. (CPRX)
  • IDEAYA Biosciences, Inc. (IDYA)
  • Disc Medicine, Inc. (IRON)
  • Legend Biotech Corporation (LEGN)
  • Mineralys Therapeutics, Inc. (MLYS)
  • Scholar Rock Holding Corporation (SRRK)

Recent insider activity

  • ROBINS HARLAN S — S-Sale (100000 shares) on 2026-06-15
  • ROBINS HARLAN S — S-Sale (6160 shares) on 2026-06-16
  • BOBULSKY SUSAN — S-Sale (5000 shares) on 2026-06-11
  • LO FRANCIS — M-Exempt (9376 shares) on 2026-06-04
  • LO FRANCIS — M-Exempt (2344 shares) on 2026-06-04

Open Adaptive Biotechnologies Corporation (ADPT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.